Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow mononuclear cell intramyocardial injection with CABG after subacute myocardial infarction
2007-004906-28Phase 2Active
- Sponsor
- Fundación Universidad de Valladolid
- Start
- Nov 2007
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in myocardial infarction (MI) (2 arms), sponsored by Fundación Universidad de Valladolid. Primary endpoints: Left ventricular functional and remodeling improvement at 9 months and Infarct-zone myocardial thickness by MRI at 9 months. Started Nov 2007; status: active.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2007-004906-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004906-28.